BioInvent's TNFR2 Antibody BI-1808 Delivers Meaningful Responses and Immune Activation as Single Agent and in Combination with KEYTRUDA(R) (pembrolizumab) in Advanced CTCL (EHA 2026)

BioInvent will host an in-person KOL lunch briefing (11:45 a.m. - 2:00 p.m. CEST / 5:45 - 8:00 a.m. EDT) in conjunction with EHA 2026 Congress today (virtual event link here)

BI-1808 monotherapy achieves 40% objective response rate (ORR), including a complete response ongoing at two years, and a 93 % disease control rate (DCR)

50% ORR and 75% DCR in combination with KEYTRUDA® (pembrolizumab)

BI-1808's Treg-depleting mechanism drives measurable immune activation in patients, confirmed by induction of IL-12, CXCL11 and CCL19 and increased CD8+ T-cell infiltration

Selectively targeting TNFR2 to deplete Tregs and reactivate anti-tumor immunity, BI-1808 holds FDA Fast Track and Orphan Drug designations in CTCL.